Results Healthcare is pleased to announce that it has advised Admescope, a Finnish contract research organisation (CRO) providing the pharmaceutical, biotechnology and veterinary industry with tailor-made ADME-Tox research services, on its acquisition by MercachemSyncom, a Netherlands-based leading mid-sized European drug-discovery contract research organisation backed by Gilde Healthcare.
This transaction highlights Results Healthcare’s expertise in delivering excellent outcomes for exciting, fast growth CRO businesses in Europe.
Admescope was founded in Oulu, Finland in 2011. It has seen significant growth in subsequent years and currently employs 40 highly qualified and experienced scientists. The scientific and management teams have consolidated experience in tailored ADME-Tox studies for pharma and biotech clients all over the world. Studies are carried out at research laboratories in both Oulu and Södertälje, Sweden with emphasis on a deep understanding of customers’ needs, in-house processes and how to design the most effective studies to satisfy them.
The acquisition will give MercachemSyncom significantly expanded capabilities for tailor-made in vitro and in vivo ADME-Tox studies for pre-clinical and early clinical R&D projects and seamless integration with the existing medicinal, synthetic and development chemistry capabilities of MercachemSyncom. Admescope brings world-class expertise in drug metabolism, drug interactions, pharmacokinetics and quantitative bioanalysis. Financial terms were not disclosed.
Dr. Ari Tolonen, CEO, Admescope:
A huge thank you to Results Healthcare for achieving this outcome with such a high quality of service. Everything went smoothly and it has been a delight to work with your committed and diligent team who were always available to provide the support we needed, no matter the time.